Home > Publications database > Results of a prospective randomized trial on long-term effectiveness of protons and carbon ions in prostate cancer: LEM I and α/β=2Gy overestimates the RBE. > print

001     180375
005     20240229145616.0
024 7 _ |a 10.1016/j.radonc.2022.06.006
|2 doi
024 7 _ |a pmid:35714806
|2 pmid
024 7 _ |a 0167-8140
|2 ISSN
024 7 _ |a 1879-0887
|2 ISSN
024 7 _ |a altmetric:129713996
|2 altmetric
037 _ _ |a DKFZ-2022-01289
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Eichkorn, T
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Results of a prospective randomized trial on long-term effectiveness of protons and carbon ions in prostate cancer: LEM I and α/β=2Gy overestimates the RBE.
260 _ _ |a Amsterdam [u.a.]
|c 2022
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1657014936_11542
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Jun 14;173:223-230
520 _ _ |a To analyze the long-term effectiveness of carbon ions relative to protons in the prospective randomized controlled ion prostate irradiation (IPI) trial.Effectiveness via PSA assessment in a randomized study on prostate irradiation with 20x3.3Gy(RBE) protons versus carbon ions was analyzed in 92 patients. Proton RBE was based on a fixed RBE of 1.1 while the local effect model (LEM) I and an α/β=2Gy was used for carbon ions. The dose in the prostate was recalculated based on the delivered treatment plan using LEM I and LEM IV and different α/β values.Five-year overall and progression free survival was 98% and 85% with protons and 91% and 50% with carbon ions, respectively, with the latter being unexpectedly low compared to Japanese carbon ion data and rather corresponding to a photon dose <72 Gy in 2 Gy fractions. According to LEM I and the applied α/β-value of 2Gy, the applied carbon ion dose in 2 Gy(RBE) fractions (EQD2) was 87.46 Gy(RBE). Recalculations confirmed a strong dependence of RBE-weighted dose on the α/β ratio as well as on the RBE-model.The data demonstrate a significant lower effectiveness of the calculated RBE-weighted dose in the carbon ion as compared to the proton arm. LEM I and an α/β = 2 Gy overestimates the RBE for carbon ions in prostate cancer treatment. Adjusting the biological dose calculation by using LEM I with α/β=4 Gy could be a pragmatic way to safely escalate dose in carbon ion radiotherapy for prostate cancer.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Carbon ion and proton radiotherapy
|2 Other
650 _ 7 |a Local effect model (LEM)
|2 Other
650 _ 7 |a Prostate cancer
|2 Other
650 _ 7 |a Relative biological effectiveness (RBE)
|2 Other
650 _ 7 |a α/β ratio
|2 Other
700 1 _ |a Karger, Christian
|0 P:(DE-He78)b43076fb0a30230e4323887c0c980046
|b 1
|u dkfz
700 1 _ |a Brons, S
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Koerber, Stefan A
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Mielke, Thomas
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Haberer, Thomas
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 6
|u dkfz
700 1 _ |a Herfarth, Klaus
|0 P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc
|b 7
773 _ _ |a 10.1016/j.radonc.2022.06.006
|g p. S0167814022041627
|0 PERI:(DE-600)1500707-8
|p 223-230
|t Radiotherapy and oncology
|v 173
|y 2022
|x 0167-8140
909 C O |p VDB
|o oai:inrepo02.dkfz.de:180375
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)b43076fb0a30230e4323887c0c980046
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-31
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOTHER ONCOL : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b RADIOTHER ONCOL : 2021
|d 2022-11-29
920 1 _ |0 I:(DE-He78)E040-20160331
|k E040
|l E040 Med. Physik in der Strahlentherapie
|x 0
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E040-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21